Search

Akero's CEO comments on today's 96 week MASH data and the future of efruxifermin
Andrew Cheng describes the F4 patient population, and dicusses the efficacy and safety data Akero saw today. Plus, ongoing trials and how...
Jan 27
Also look for unique social pages for BiotechTV U.
Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.